cyclosporine-polyglycol

Cyclosporine-polyglycol appears to be a formulation or conjugate involving cyclopsorine, an immunosuppressant, and a polyglycol component, likely intended to modify the pharmacokinetics, delivery, or solubility of cyclosporine. Cyclosporine is a calcineurin inhibitor that acts by inhibiting T cell activation through formation of a cyclosporine–cyclophilin complex, preventing activation of nuclear factor of activated T cells (NF-AT) and subsequent cytokine production including IL-2, IL-4, interferon-gamma, and TNF-alpha. This results in strong immunosuppressive effects, used mainly for prevention of organ transplant rejection and treatment of autoimmune diseases. The polyglycol moiety is not standard in approved cyclosporine medications and may represent an experimental or modified formulation; however, no definitive information is available in public sources confirming this specific conjugate or formulation as a distinct marketed product[1][3][5].

Brand names

cyclosporine-polyglycol

Other names

cyclosporine-polyglycol